A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects With Cystic Fibrosis Aged 18 Years or Older
Overview
- Phase
- Phase 2
- Intervention
- Diponecaftor
- Conditions
- Cystic Fibrosis
- Sponsor
- Kors van der Ent
- Enrollment
- 41
- Locations
- 16
- Primary Endpoint
- Mean percent predicted forced expiratory volume in 1 second (ppFEV1)
- Status
- Completed
- Last Updated
- 5 months ago
Overview
Brief Summary
CF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of action are needed. To date, clinical studies of CFTR modulators have focused on patients carrying the F508del CFTR mutation, which is present in approximately 80% of CF patients, or gating mutations which are present in 5% of CF patients (gating mutations result in a reduced opening of the CFTR-channel at the cell surface which limits the flow of chloride ions through the CFTR channel). Although CF is a monogenetic disease, the 15% remaining patients represent more than 2000 different rare and mostly uncharacterized CFTR mutations. Multiple pharma companies have one or more CF drugs in their developmental pipeline. However, it is not known which patients may respond to the drugs in the pipeline. It is hypothesized that by using individual patient's intestinal organoids to screen for drug response, a subset of patients with rare CFTR mutations can be identified who will clinically respond to drugs in the developmental pipeline. The Human Individualized Therapy of CF (HIT-CF) project has been designed to further evaluate this hypothesis. The project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 755021. The core of the project consists of a two-step approach to identify patients outside the existing drug label who may also benefit from CFTR-modulator treatment. In the first step of the project (HIT-CF Organoid Study, NTR7520), novel CFTR modulators and their combinations were tested on organoids from over 500 European and Israeli CF patients with rare CFTR mutations to identify patients who are predicted to clinically benefit from these treatments. The second step will evaluate the predicted clinical effect of the CFTR modulators in subjects identified by their organoid response to investigational products. CFTR modulators from the HIT-CF participating pharmaceutical company, FAIR Therapeutics, will be evaluated in the CHOICES clinical study described in this protocol. Data from this clinical study will be compared with the HIT-CF Organoid Study results to validate the organoid model.
Investigators
Kors van der Ent
Project Leader and Coordinating Investigator
UMC Utrecht
Eligibility Criteria
Inclusion Criteria
- •A subject must meet ALL the following criteria in order to participate:
- •Male or female subjects who completed the HIT-CF Organoid Study and are 18 years of age or older on the date of informed consent
- •Confirmed diagnosis of CF as follows:
- •Sweat chloride value of ≥60 mmol/L based on quantitative pilocarpine iontophoresis (at screening) OR 2 CF-causing mutations AND
- •chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities
- •Clinically stable CF disease in the opinion of the investigator with no significant changes in health status within 28 days prior to Day 1
- •Forced expiratory volume in one second (FEV1) ≥40% of predicted to ≤90% of predicted at the Screening Visit, based on the Global Lung Function Initiative (GLI) -2012 multi-ethnic all-age reference equations
- •Body mass index (BMI) ≥16 kg/m2 and ≤30 kg/m2
- •Non-smoker and non-tobacco user (including all inhalational nicotine delivery systems) for a minimum of 30 days prior to screening, and subject agrees not to smoke or use tobacco for the duration of the study
- •Subjects of childbearing potential must meet contraception requirements (Section 13.3.1)
Exclusion Criteria
- •A subject who meets ANY of the following criteria will be excluded from participation:
- •Subject has at least one of the following CFTR-mutations: F508del, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H, A455E, 3849+10kbC\>T OR A combination of any two of the following mutations: any nonsense mutation, 1717-1G\>A, 621+1G\>T, 3120+1G\>A, 1898+1G-\>A, CFTRdele2,3, and 2183AA-\>G
- •History or current evidence of any clinically significant cardiac (eg, heart failure, left ventricular hypertrophy, myocardial infarction, and arrhythmia), endocrinologic, hematologic, hepatobiliary (eg, clinically significant cirrhosis with or without portal hypertension, hepatitis B or hepatitis C), immunologic, metabolic, urologic, pulmonary (besides CF), neurologic (eg, subarachnoid haemorrhage, intracranial haemorrhage, cerebrovascular accident, intracranial trauma, and autonomic neuropathy), dermatologic, psychiatric, renal, or other major disease, that is unstable or could interfere with the subject's participation in or completion of the study, in the opinion of the investigator
- •Clinically significant screening results that would exclude subject from the study (eg, medical history, physical examination, ECG, vital sign, pulse oximetry, and laboratory profiles) or any conditions that, would make the subject unsuitable for enrolment or could interfere with the subject's participation in or completion of the study, in the opinion of the investigator. The medical monitor must be contacted for review of any subjects with screening results or conditions that may make them unsuitable for enrolment or could interfere with participation in or completion of the study.
- •Prolonged QTcF \>450 msec at screening
- •Abnormal liver function as defined by AST, ALT, gamma-glutamyl transferase (GGT), or alkaline phosphatase ≥3 times or total bilirubin ≥2 times upper limit of the normal range
- •Haemoglobin \<10 g/dL
- •Platelet count \<150,000 cells/mm3
- •Abnormal renal function at screening defined as creatinine clearance \<60 mL/min using the Modified Diet in Renal Disease (MDRD)
- •Hospitalisation, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness (in the opinion of the investigator) requiring an increase or addition of medication, such as antibiotics or corticosteroids, within 28 days of Day 1
Arms & Interventions
Diponecaftor/Placebo
Diponecaftor once daily for 8 weeks followed by placebo once daily for 8 weeks. In between both periods there will be a washout period to minimize a possible carryover effect.
Intervention: Diponecaftor
Diponecaftor/Placebo
Diponecaftor once daily for 8 weeks followed by placebo once daily for 8 weeks. In between both periods there will be a washout period to minimize a possible carryover effect.
Intervention: Placebo
Placebo/Diponecaftor
Placebo once daily for 8 weeks followed by diponecaftor once daily for 8 weeks. In between both periods there will be a washout period to minimize a possible carryover effect.
Intervention: Diponecaftor
Placebo/Diponecaftor
Placebo once daily for 8 weeks followed by diponecaftor once daily for 8 weeks. In between both periods there will be a washout period to minimize a possible carryover effect.
Intervention: Placebo
Outcomes
Primary Outcomes
Mean percent predicted forced expiratory volume in 1 second (ppFEV1)
Time Frame: Measurements taken at 4, 6 and 8 weeks of treatment
The primary endpoint in both groups is the mean percent predicted forced expiratory volume in 1 second (ppFEV1) of measurements taken after 4, 6 and 8 weeks of treatment. Period baseline values will be corrected for in the analysis.
Secondary Outcomes
- Sweat chloride(Measurements taken at 4, 6 and 8 weeks of treatment)
- Body weight(Measurements taken at 4, 6 and 8 weeks of treatment)
- Cystic Fibrosis Questionnaire Revised (CFQ R) respiratory domain(Measurements taken at 4, 6 and 8 weeks of treatment)
- Safety and tolerability assessments(Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment)